Objective The aim of the study to was to evaluate safety and efficacy of the new generation flow diverter device, Surpass Evolve (SE).

Methods In two Finnish early-user centers, twenty-seven patients with ruptured or unruptured intracranial aneurysms were treated with SEs. All procedure-related events were recorded into the local database for further analysis. We report here our results concerning the clinical and radiological results from intracranial aneurysms treated with this new generation flow diverter device, SE.

Results Twenty-eight aneurysms (86% unruptured) were treated with twenty-nine SE devices. All procedures were technically successful. In one aneurysm (case #26), a coil was used to secure the thrombosis. At discharge, all patients had a modified Rankin score of 0–2. No intraprocedural or thromboembolic complications were encountered. One subarachnoid hemorrhage (SAH) occurred one week after the treatment (case #22), and this patient died due to SAH. The median follow-up time was two months (range; 0–6 months). The radiological follow-up data was available for nine patients (33%); two aneurysms were occluded during the follow-up period.

Conclusions Our initial experience with the new generation SE indicates that the device is safe to use. The new generation SE provides reliable deployment and lower foreshortening. Mid-term and long-term follow-up examinations will be needed to provide data on longer term safety outcomes.

Disclosures K. Alpay: None. R. Rautio: 2; C; Microvention, Stryker, Medtronic. J. Numminen: None. M. Sinisalo: None.